SI2641601T1 - Postopek za zdravljenje multiple mielome z uporabo kombinacijskih terapij, osnovanih na HuLuc63 z bortezomibom - Google Patents

Postopek za zdravljenje multiple mielome z uporabo kombinacijskih terapij, osnovanih na HuLuc63 z bortezomibom

Info

Publication number
SI2641601T1
SI2641601T1 SI200731803A SI200731803A SI2641601T1 SI 2641601 T1 SI2641601 T1 SI 2641601T1 SI 200731803 A SI200731803 A SI 200731803A SI 200731803 A SI200731803 A SI 200731803A SI 2641601 T1 SI2641601 T1 SI 2641601T1
Authority
SI
Slovenia
Prior art keywords
huluc63
bortezomib
methods
multiple myeloma
combination therapies
Prior art date
Application number
SI200731803A
Other languages
English (en)
Slovenian (sl)
Inventor
Daniel Afar
Kenneth C. Andersen
Yu-Tzu Tai
Original Assignee
Abbvie Biotherapeutics Inc.
Dana-Faber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2641601(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc., Dana-Faber Cancer Institute, Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of SI2641601T1 publication Critical patent/SI2641601T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
SI200731803A 2006-08-07 2007-08-07 Postopek za zdravljenje multiple mielome z uporabo kombinacijskih terapij, osnovanih na HuLuc63 z bortezomibom SI2641601T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
EP13168383.1A EP2641601B8 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib

Publications (1)

Publication Number Publication Date
SI2641601T1 true SI2641601T1 (sl) 2016-11-30

Family

ID=38831279

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731641T SI2068874T1 (sl) 2006-08-07 2007-08-07 Postopki zdravljenja multiplega mieloma z uporabo kombinacijske terapije utemeljene na anti-csi protitelesih
SI200731803A SI2641601T1 (sl) 2006-08-07 2007-08-07 Postopek za zdravljenje multiple mielome z uporabo kombinacijskih terapij, osnovanih na HuLuc63 z bortezomibom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200731641T SI2068874T1 (sl) 2006-08-07 2007-08-07 Postopki zdravljenja multiplega mieloma z uporabo kombinacijske terapije utemeljene na anti-csi protitelesih

Country Status (23)

Country Link
US (4) US8632772B2 (OSRAM)
EP (5) EP2942057A1 (OSRAM)
JP (1) JP5340935B2 (OSRAM)
CN (1) CN101686971B (OSRAM)
AU (1) AU2007281684C1 (OSRAM)
BR (1) BRPI0716647A2 (OSRAM)
CA (1) CA2660356C (OSRAM)
CY (5) CY1116247T1 (OSRAM)
DK (2) DK2641601T3 (OSRAM)
ES (2) ES2535437T3 (OSRAM)
HR (2) HRP20150449T1 (OSRAM)
HU (4) HUE029027T2 (OSRAM)
IL (2) IL196919A (OSRAM)
LT (4) LT2641601T (OSRAM)
LU (3) LU93277I2 (OSRAM)
MX (1) MX2009001441A (OSRAM)
NL (1) NL300840I2 (OSRAM)
NO (1) NO346835B1 (OSRAM)
NZ (1) NZ574978A (OSRAM)
PL (2) PL2068874T3 (OSRAM)
PT (2) PT2068874E (OSRAM)
SI (2) SI2068874T1 (OSRAM)
WO (1) WO2008019378A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2068930E (pt) 2006-08-07 2012-10-23 Abbott Biotherapeutics Corp Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo
CA2660356C (en) 2006-08-07 2016-04-05 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
CA3138282A1 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
AU2009271401A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
EA024364B1 (ru) * 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
AU2010293383B2 (en) 2009-09-10 2014-12-18 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4)
MX2012005849A (es) * 2009-11-24 2012-08-23 Celgene Corp Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d.
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
EP2914278B1 (en) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
PL3071597T3 (pl) * 2013-11-21 2020-11-30 F.Hoffmann-La Roche Ag Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
JP7120763B2 (ja) * 2014-08-22 2022-08-17 セルジーン コーポレイション 免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
RU2723047C2 (ru) 2015-05-13 2020-06-08 МорфоСис АГ Средство для лечения множественной миеломы (ММ)
ES2886657T3 (es) * 2015-06-29 2021-12-20 Bristol Myers Squibb Co Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
CN109395058A (zh) * 2016-03-13 2019-03-01 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
EP3601365A4 (en) * 2017-03-29 2021-01-13 Agency for Science, Technology and Research ANTI-OLIGOSACCHARIDE ANTIBODIES
CN111373246A (zh) * 2017-11-22 2020-07-03 希成生物医药 包括硼替佐米的聚合物纳米颗粒
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
KR20220092578A (ko) 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
EP0831860B1 (en) 1995-05-25 2004-10-20 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
SI1505973T1 (sl) * 2002-05-17 2010-06-30 Celgene Corp Kombinacija za zdravljenje multiplega mieloma
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US20090175866A1 (en) * 2004-11-04 2009-07-09 Avner Yayon Treatment of b-cell malignancies
CA2660356C (en) 2006-08-07 2016-04-05 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
PT2068930E (pt) * 2006-08-07 2012-10-23 Abbott Biotherapeutics Corp Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo
WO2008019379A2 (en) 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
IL243933A0 (en) 2016-04-21
LTPA2016029I1 (lt) 2016-11-10
SI2068874T1 (sl) 2015-06-30
IL196919A0 (en) 2009-11-18
EP2641600A1 (en) 2013-09-25
CY1116247T1 (el) 2017-02-08
HUE029027T2 (en) 2017-01-30
HUS1600045I1 (hu) 2016-12-28
MX2009001441A (es) 2009-07-06
EP3115049A1 (en) 2017-01-11
US20170342150A1 (en) 2017-11-30
CY2016036I1 (el) 2017-07-12
LT2641601T (lt) 2016-10-10
CY2016038I1 (el) 2017-07-12
CY2016036I2 (el) 2017-07-12
CA2660356C (en) 2016-04-05
US20080152646A1 (en) 2008-06-26
EP2068874A1 (en) 2009-06-17
EP2641601B1 (en) 2016-07-06
JP2010500371A (ja) 2010-01-07
HK1129853A1 (en) 2009-12-11
DK2068874T3 (da) 2015-04-27
NL300840I2 (OSRAM) 2017-01-03
CA2660356A1 (en) 2008-02-14
US20160137735A1 (en) 2016-05-19
NO20090968L (no) 2009-04-30
EP2641601A1 (en) 2013-09-25
LTPA2016030I1 (lt) 2016-11-10
LU93277I2 (fr) 2016-12-27
EP2641601B8 (en) 2016-09-21
EP2068874B1 (en) 2015-01-28
HRP20150449T1 (xx) 2015-06-05
LTPA2016031I1 (lt) 2016-11-10
PL2641601T3 (pl) 2017-01-31
CN101686971A (zh) 2010-03-31
JP5340935B2 (ja) 2013-11-13
AU2007281684B2 (en) 2013-05-16
IL196919A (en) 2016-03-31
HUS1600043I1 (hu) 2016-12-28
CN101686971B (zh) 2013-09-11
HRP20161284T1 (hr) 2016-12-16
AU2007281684C1 (en) 2013-12-19
PT2641601T (pt) 2016-10-14
LU93275I2 (fr) 2016-12-27
LU93276I2 (fr) 2016-12-27
BRPI0716647A2 (pt) 2017-05-16
PL2068874T3 (pl) 2015-06-30
US8632772B2 (en) 2014-01-21
ES2535437T3 (es) 2015-05-11
DK2641601T3 (en) 2016-08-22
NZ574978A (en) 2012-08-31
CY1117992T1 (el) 2017-05-17
US20140322201A1 (en) 2014-10-30
ES2589302T3 (es) 2016-11-11
EP2942057A1 (en) 2015-11-11
NO346835B1 (no) 2023-01-23
AU2007281684A1 (en) 2008-02-14
LTC2068874I2 (lt) 2018-11-12
CY2016037I1 (el) 2017-07-12
HUS1600044I1 (hu) 2016-12-28
PT2068874E (pt) 2015-05-21
WO2008019378A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
LT2641601T (lt) Daugybinės mielomos, naudojant kombinuotas terapijas, pagrįstas huluc63 su bortezomibu, gydymo būdai
IL257418A (en) Methods for treating addiction
DK3067067T3 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
IL193920A0 (en) Methods of treating lupus using cd4 antibodies
ZA200807715B (en) 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
EP2114553A4 (en) SYSTEM AND METHOD FOR INJECTING INHIBITORS
GB2467710B (en) Methods for treating social disorders
IL213476A0 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
SI2029155T1 (sl) Izboljšano zdravljenje multiplega mieloma
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
IL209360A0 (en) Multiple myeloma treatments
PL2131841T3 (pl) Sposoby leczenia bólu ostrego
EP2205271A4 (en) COMPOSITIONS AND METHODS OF THERAPIES BASED ON RIBONUCLEASE BASE
ZA200807524B (en) Methods of treating lupus using CD4 antibodies
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
ZA200903242B (en) Treatment for multiple myeloma
HK1131318A (en) Methods of using saha and bortezomib for treating multiple myeloma
HK1167807A (en) Combination therapy for the treatment of multiple myeloma using cep-18770 together with bortezomib or mephalan
ZA201000867B (en) Methods for treating dependence
GB0619251D0 (en) T cell therapies